← Back to Search

Anti-infective

Intranasal Povidone Iodine for Asymptomatic Colonization

Phase 4
Recruiting
Led By Mary K. Hayden, MD
Research Sponsored by Mary K Hayden
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History of C. auris colonization or infection
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion and data analysis in three years (2028)
Awards & highlights

Study Summary

This trial will test whether using a specific type of antiseptic in the nose can help in detecting a type of fungus called Candida auris.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had a C. auris infection or been colonized by it.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion and data analysis in three years (2028)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion and data analysis in three years (2028) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Detection of C. auris from the anterior nares
Secondary outcome measures
Detection of C. auris from body sites other than anterior nares
Detection of C. auris from environmental surfaces
Detection of MRSA from environmental surfaces
+1 more
Other outcome measures
Change in microbiome community
Non-susceptibility of C. auris to povidone iodine

Trial Design

2Treatment groups
Active Control
Group I: ControlActive Control1 Intervention
Routine care.
Group II: Intranasal Povidone IodineActive Control1 Intervention
Nasal iodophor applied twice daily for five days.

Find a Location

Who is running the clinical trial?

Mary K HaydenLead Sponsor
Rush University Medical CenterOTHER
424 Previous Clinical Trials
156,615 Total Patients Enrolled
RML Specialty HospitalOTHER
4 Previous Clinical Trials
811 Total Patients Enrolled
~80 spots leftby Dec 2026